Huons Meditech Accelerates Overseas Marketing
Huons Meditech Accelerates Overseas Marketing
- Participation in SIU 2024 and ICAP 2024... Efforts to Expand Global Influence -
▲ Huons Meditech participated in the "SIU 2024" held in New Delhi, India, and introduced the lithotripter "URO-UEMXD." Visitors are taking photos after the announcement of the theme of "ESWL's Latest Trends." LEE Jin-suk, CEO of Huons Meditech, is on the left side of the front row of the photo
Huons Meditech Co., Ltd., under the leadership of CEO LEE Jin-suk, recently announced its participation in the 2024 Congress of the Société Internationale d’Urologie (SIU 2024) held in New Delhi, India. Through this event, the company sought to demonstrate its advanced technology and strengthen its competitive presence on the global stage.
SIU, established in 1907, is one of the most distinguished international platforms focused on urological diseases and treatments, drawing thousands of experts from over 100 countries each year. Attendees engage in sessions and exhibitions that discuss the latest technological advancements and treatment methods shaping global urology.
At SIU 2024, Huons Meditech showcased its URO-UEMXD, an extracorporeal shock wave lithotripter (ESWL) that combines a shock wave head and an inline ultrasound probe, setting it apart from traditional X-ray-based devices. This innovative approach enables both diagnosis and treatment of opaque and non-opaque urinary stones through ultrasound, allowing for heightened precision and minimizing reliance on X-ray imaging. The URO-UEMXD, developed in collaboration with India’s Vasu Group, was well-received at the event, underscoring Huons Meditech’s intention to capture a substantial portion of the global urology market.
Further enhancing the company’s impact, Professor Yoon Hana, Korea’s first female urologist, presented on “The Current Trend of ESWL in Urolithiasis.” Her discussion emphasized the URO-UEMXD’s clinical efficacy and safety, supporting these claims with research findings that highlighted improved treatment outcomes and patient comfort.
In addition to SIU 2024, Huons Meditech participated in the ICAP 2024 (International Congress of ASLS & Perdaweri Banten) in Jakarta, Indonesia. Here, the focus shifted to strengthening the company’s influence in the global beauty device market, underscoring Huons Meditech’s diverse portfolio and international ambitions.
LEE Jin-suk (CEO) noted that participating in these prominent international conferences has provided Huons Meditech with valuable exposure and networking opportunities, furthering the company’s reach in both the Indian and Indonesian markets. Emphasizing collaboration with global partners, he expressed the company’s commitment to actively expand its market share through strategic partnerships and continued innovation.
▲ Huons Meditech participated in the "ICAP 2024" held in Jakarta, Indonesia, and is conducting promotional activities by informing visitors of product excellence.
Huons Meditech Wins DermaShine Trademark Case in China
Huons Meditech Expands into the Japanese Market with ‘Dermashine Duo_RF’
Huons Meditech Targets Southeast Asia Market at 'AMUSE 2026' in Indonesia
Huons Meditech Targets Latin American Market at 'Hospitalar 2026' Exhibition in Brazil
Huons Meditech Receives CE-MDR Approval for Aesthetic Drug Delivery System ‘Premium 9-Pin Needle’
Huons Meditech Strengthens Educational and Academic Marketing for Aesthetic Medical Device ‘Dermashine’
Humedix and Huons Meditech Sign Tripartite MOU with V&Co to Expand AI-powered Skin Diagnostics Business
Huons Meditech Showcased Innovative Medical Devices at ‘KIMES 2026’
Huons Group Chairman Yoon Sung-tae Attends in Inauguration of Endoscope Washer-Disinfector Production Line at India’s Vasu Group
Huons Meditech Showcases at ‘WHX Dubai 2026’
Huons Meditech Officially Launches ‘Dermashine Duo RF’, Combining Drug Delivery with Radiofrequency
Huons Meditech Participates in MEDICA 2025 in Germany